With a market cap of $62.4 billion, Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology.

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo.

Total revenues increased 10% year over year to $3.79 billion, fueled by increased collaboration revenues from Sanofi for Dupixent, higher Eylea HD and Libtayo sales. Revenues marginally beat the ...

Regeneron's (REGN) REGN7075, in combination with its oncology drug Libtayo, generates anti-tumor responses in patients with microsatellite-stable colorectal cancer.

Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that the completion ...

Based in Tarrytown, New York, the company’s products include EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, and Kevzara. More Top Stocks Daily: Go behind Wall Street’s hottest headlines with ...